Hepatocellular Carcinoma: From early detection to effective therapy

By
Prof. Dr. Ayman Menessy
MD. Internal Medicine
Hepato-gastroenterology unit
Mansoura Faculty of Medicine
Historical review

• Rokitansky (1849): was the first author to refer to primary liver carcinoma.
• Noeggerath (1854): described a congenital hepatic carcinoma.
• Billroth (1859): reported the presence of hepatic metastases.
• In 1881: Sabourin was the first to term “hepatoma”.
• Price (1883): described the development of hepatoma from cirrhosis.
• The first righ-sided lobectomy for hepatic carcinoma was carried out in 1911.
Epidemiology

• HCC is now the fifth common cancer in the world and third cause of cancer related mortality.

• More than half a million cases are diagnosed every year which closely resembles the number of deaths (598,000)/year.

• It is 3 times more common in men than in women, higher levels of testosterone, lower levels of estrogens, higher rates of liver disease are proposed explanation.
• The age at which HCC appears varies according to gender, geographic area and risk factors.

• It has high incidence rates in: Eastern Asia and sub-Saharan Africa (>15/100,000) population intermediate rate (5-15/100,000) in Mediterranean basin and southern Europe.

• Very low (<5/100,000) in Northern Europe and America.
• **In Egypt:**
  
  – HCC proportion had increased in the last years from 4.0% to 7.2% among chronic liver disease patients *(El-Zayadi et al., 2005)*

• HCC is the 2nd most frequent cancer in males, the 4th in females and constituted 13% of all cancer in Egypt *(El Attar, 2005)*.
Age standardized incidence per 100.000 inhabitants.
Condition associated with HCC

- **Hepatitis viruses:**
  - HBV, HCV
- **Liver disease**
  - Chronic hepatitis
  - Cirrhosis
  - NASH
- **Mycotoxins or phytotoxins**
  - Afltoxin
  - Microcystin
  - Cycasin
  - Ochratoxin
  - Luteoskyrin
  - Safrol
  - maltrozym
• **Nutrition:**
  – Alcohol
  – Ethionine surplus
  – Betel quid chewing
  – Tobacco smoke
  – B6 and choline deficiency.

• **Metabolic diseases:**
  – Alpha1- antitrypsin deficiency
  – Colon polyposis
  – Galactosaemia
  – Glycogenosis type 1.
  – Haemochromatosis
  – Neurofibromatosis
  – Porphyria
  – Tyrosinaemia type 1
• **Chemical agents**
  – Alkylating agents
  – Nitrose compounds
  – Aromatic amines
  – Vinyl chloride
  – Azo-compounds.

• **Inorganic substances**
  – Arsenic, asbestos
  – Lead, manganese
  – Cadmium, chromium
  – Nickel

• **Medications**
  – Androgens, anabolic, contraceptives
  – Metyldopa, methotrexate.

• **Ionizing radiation:**
  – Thorium
  – X-ray
Major risk factor

- **HBV:**
  - 5-15 fold increased risk
  - 70-90% of cases in setting of cirrhosis
  - Treatment does not decrease risk.
  - Early vaccination: associated with a decrease in risk of cancer in children from 0.54 to 0.20 per 100,000 during a 16 year period.

- **HCV**
  - 1-3% of HCV cirrhotic patient.
  - Treatment seems to decrease risk
• **Co-infection:**
• **Aflatoxins**: Associated with 4 folds risk of HCC
• **Smoking**: synergistic with HCV and HBV
• **Alcohol**: no direct carcinogenic effect, but synergistic with HBV, HCV.

**Genetic mechanism:**

– It is observed that more than 22% of patients suffering from HCC had other organ tumors as well.
– Patients with obesity and diabetes mellitus, also have a higher risk of HCC.
– Several hereditary metabolic disease, with or without cirrhosis, may increase risk of HCC.
Clinical features:

• HCC can develop without subjective complaints.
• The complaint may be general, undetected
• May be explained as a symptoms of cirrhosis or pre-existing chronic liver disease.
• **General**
  – Pain in upper abdomen
  – Weight loss
  – Bloating, flatulence
  – Fatigue, weakness
  – Nausea
  – Disturbed bowel habit

• **Specific:**
  – Fever
  – Arterial mumur
  – Icterus
  – Tender upper abd.
  – Ascites
  – Palpable tumor
  – Latent encephalopathy
  – Perihepatic friction
• **Paraneoplastic findings**
  – Polycythaemia
  – Hypercalciemia
  – Painful gynaecomastia
  – Hyperthyrodisn
  – Esteoarthropathy
  – Hypertension
  – Pseudo porphyria
  – Polyneuropathy
  – Watery diarrhea
  – hypoglycemia
Screening for HCC

**Aim:** to detect early as possible the tumor for better outcome.

**Abdominal ultrasound:**
- Better than serologic tests.
- Sensitivity 65-80%, specificity >90%

**AFP**
- Sensitivity not more than 50%.
- Poor screening test.
- Should not be used alone.
- Other serology: des-y-carboxy prothrombin
- Addose A.
- α-L-flucosidase
The best screening for early detection

• Combination of:
  – All cirrhotic
  – Interval better not more than 6 months.
  – Abd. US
  – AFP
  – Any alarm sign or poor response to treatment.
<table>
<thead>
<tr>
<th>Groups recommended to be under screening for HCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B carriers</td>
</tr>
<tr>
<td>Asian men &gt;40 y</td>
</tr>
<tr>
<td>Asian women &gt;50y</td>
</tr>
<tr>
<td>All cirrhotic hepatitis B carriers</td>
</tr>
<tr>
<td>Family history of HCC</td>
</tr>
<tr>
<td>Africans &gt;20 y</td>
</tr>
<tr>
<td>Patients with high HBV DNA and ongoing hepatic injury remain at risk of HCC.</td>
</tr>
<tr>
<td>Non-hepatitis B cirrhosis</td>
</tr>
<tr>
<td>Hepatitis C</td>
</tr>
<tr>
<td>Alcoholic cirrhosis</td>
</tr>
<tr>
<td>Genetic hemochromatosis</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>Insufficient data to make recommendations</td>
</tr>
<tr>
<td>Cirrhosis due to $\alpha_1$–anitrypsin deficiency</td>
</tr>
<tr>
<td>Cirrhosis due to nonalcoholic steatohepatitis</td>
</tr>
<tr>
<td>Cirrhosis due to autoimmune hepatitis.</td>
</tr>
</tbody>
</table>

*HBV, hepatitis B virus.*
Prognosis of HCC depend on:

- Patients: related factors: age, sex, race
- Liver related factors: liver cirrhosis, hepatitis, hepatic functional reserve
- Tumor related factors: pathological features, tumour markers, molecular markers
- The treatment modality
Unfavorable characteristics:

- T4 tumours
- AFP level > 1,000 ng/ml.
- Total tumour diameters > 8 cm.
- Vascular invasion
- Poorly differentiated histologic grade
- Older individuals
Staging of HCC

- Multiple clinical systems for hepatic tumours have been described. The most widely used is:
  - Barceletona clinic system (BCLC)
  - Cancer of the liver Italian program (CLIP)
  - American joint commission on cancer staging (AJCC/TNM).
  - The Okuda staging system (1984).
# The Okuda staging system

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor size</td>
<td>&gt;50%</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>&lt;50%</td>
<td>0</td>
</tr>
<tr>
<td>Asites</td>
<td>Present</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Absent</td>
<td>0</td>
</tr>
<tr>
<td>Serum albumin</td>
<td>&gt;3</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>&lt;3</td>
<td>1</td>
</tr>
<tr>
<td>Serum bilirubin</td>
<td>&gt;3</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>&lt;3</td>
<td>0</td>
</tr>
<tr>
<td>Stage 1</td>
<td>0 points</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1-2 points</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3-4 points</td>
<td></td>
</tr>
</tbody>
</table>
Cancer of the liver Italian program (CLIP)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>1. Morphology and hepatic replacement</td>
<td></td>
</tr>
<tr>
<td>Single &lt; 50%</td>
<td></td>
</tr>
<tr>
<td>Multiple &lt; 50%</td>
<td></td>
</tr>
<tr>
<td>&gt; 50%</td>
<td></td>
</tr>
<tr>
<td>2. Child-Pugh Score</td>
<td>A</td>
</tr>
<tr>
<td>&lt;400</td>
<td></td>
</tr>
<tr>
<td>≥ 400</td>
<td></td>
</tr>
<tr>
<td>3. AFP (ng/ml)</td>
<td>No</td>
</tr>
<tr>
<td>4. Portal vein thrombosis</td>
<td></td>
</tr>
</tbody>
</table>

This staging system used classic techniques of analysis of variables. It only included patients with cirrhosis and uses Child-Pugh score rather than its individual components.

$^b$Score = sum of points for four variables
<table>
<thead>
<tr>
<th>Primary tumor (T)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX: Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0: No evidence of primary tumor</td>
</tr>
<tr>
<td>T1: Solitary tumor without vascular invasion</td>
</tr>
<tr>
<td>T2: Solitary tumor with vascular invasion, or</td>
</tr>
<tr>
<td>Tumor involving a major branch of the portal or</td>
</tr>
<tr>
<td>hepatic vein (s)</td>
</tr>
<tr>
<td>T3: Multiple tumors no more than 5 cm</td>
</tr>
<tr>
<td>T4: Multiple tumors more than 5 cm or Tumor involving</td>
</tr>
<tr>
<td>a major branch of the portal or hepatic vein (s)</td>
</tr>
<tr>
<td>Tumor(s) with direct invasion of adjacent organs other</td>
</tr>
<tr>
<td>than the gallbladder or with perforation of</td>
</tr>
<tr>
<td>visceral peritoneum</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regional lymph node (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX: Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0: No regional lymph node metastasis</td>
</tr>
<tr>
<td>NI: Regional lymph node metastasis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Distant metastasis (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MX: Distant metastasis cannot be assessed</td>
</tr>
<tr>
<td>M0: No distant metastasis</td>
</tr>
<tr>
<td>MI: Distant metastasis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage grouping</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0 N0 T1 I</td>
</tr>
<tr>
<td>M10 N0 T2 II</td>
</tr>
<tr>
<td>M0 N0 T3 III A</td>
</tr>
<tr>
<td>M0 N0 T4 III B</td>
</tr>
<tr>
<td>M0 NI Any T III C</td>
</tr>
<tr>
<td>Any N M1Arty T IV</td>
</tr>
</tbody>
</table>

(From ref. 224, with permission.)
<table>
<thead>
<tr>
<th>Treatment options for hepatocellular carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surgery</strong></td>
</tr>
<tr>
<td>partial hepatectomy</td>
</tr>
<tr>
<td>liver transplantation</td>
</tr>
<tr>
<td><strong>Local ablative therapies</strong></td>
</tr>
<tr>
<td>cryosurgery</td>
</tr>
<tr>
<td>microwave ablation</td>
</tr>
<tr>
<td>ethanol injection</td>
</tr>
<tr>
<td>acetic acid injection</td>
</tr>
<tr>
<td>Radiofrequency ablation</td>
</tr>
<tr>
<td><strong>Regional therapies:</strong> hepatic artery transcatheter treatments</td>
</tr>
<tr>
<td>transarterial chemotherapy</td>
</tr>
<tr>
<td>transarterial embolization</td>
</tr>
<tr>
<td>transarterial chemoembolization</td>
</tr>
<tr>
<td>transarterial radiotherapy</td>
</tr>
<tr>
<td>$^{90}$Y microspheres</td>
</tr>
<tr>
<td>$^{131}$I lipiodol</td>
</tr>
<tr>
<td><strong>Conformal external-beam radiation therapy</strong></td>
</tr>
<tr>
<td><strong>Systemic therapies</strong></td>
</tr>
<tr>
<td>chemotherapy</td>
</tr>
<tr>
<td>Immunotherapy</td>
</tr>
<tr>
<td>Hormonal therapy + growth control</td>
</tr>
<tr>
<td><strong>Supportive care</strong></td>
</tr>
</tbody>
</table>
Curative TTT for Early Stage HCC

• Liver Transplantation / Resection.

• Radiofrequency Ablation (RFA).

• Percutaneous Ethanol or Acetic acid ablation.

• Microwave ablation.
Palliative TTT for Advanced Stage HCC

- Transart. chemoembolization (TACE).
- Radiation therapy.
- Systemic chemotherapy.
1- Surgical resection

The backbone of curative treatment in patients with early HCC.
Favourable criteria for surgical resection

- **Single nodules** < 5 cm in size or a maximum of 3 nodules ≤ 3 cm in a single liver lobe.

- **In patients with:**

  1. Mildly impaired liver function (Child A).
  2. Without portal hypertension:
     - Hepato-portal-venous pressure gradient < 10 mm Hg.
     - No esophageal varices.
     - Absence of splenomegaly.
  3. Platelet counts > 100,000/μl and
  3. Serum bilirubin in the normal range.
PANORAMA OF DIFFERENT SURGICAL SPECIMEN OF HEPATOMA
**Optimal Criteria**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitary tumor &lt; 5 cm</td>
<td></td>
</tr>
<tr>
<td>No vascular invasion</td>
<td></td>
</tr>
<tr>
<td>No portal hypertension</td>
<td></td>
</tr>
<tr>
<td>Well-preserved hepatic function (Child-Pugh Class A)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage 1-2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5 yr OS</td>
<td>Ranges ≈ 40% - 90%</td>
</tr>
<tr>
<td>Long term recurrence free</td>
<td>≈40%</td>
</tr>
</tbody>
</table>

- Resection should be considered the standard therapy for patients with HCC who have adequate liver reserve.
Offers better survival rates than resection by offering both decreased tumor recurrence and a treatment of the underlying liver disease.
Indication

Is an alternative therapeutic option:

1- If the liver cancer cannot be cured by local resection due to anatomical reasons.

2- If residual liver function after resection is anticipated to be poor.

3- If there is multi-nodular tumor spread into both liver lobes.
Solitary nodule with < 5 cm of diameter, or
≤ 3 nodules with each ≤ 3 cm of diameter.

No gross vascular invasion.

No lymph nodes involvement.

• Milano’s criteria patients usually achieve survival rates of 80% and 70% one and five years after liver transplantation.
Beyond Milano’s criteria

- **1112 exceeding Milano’s criteria:**
  - Median size of largest nodule: 4cm
  - Median numbers of nodules: 4
  - 41% of microvascular invasion (worst prognostic factor).

- **5-years overall survival 53% vs 73% in patient meet Milano’s criteria.**

Mazzaferro V. et al. Lancet 2009
Anastomosis between celiac tripode of the graft and accessory left hepatic artery of the receiver.
### Optimal Criteria

<table>
<thead>
<tr>
<th>Condition</th>
<th>Stage 1-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitary tumor &lt; 5 cm</td>
<td>3 yr OS</td>
</tr>
<tr>
<td>Up to three nodules ≤3 cm</td>
<td>≈ 75%</td>
</tr>
<tr>
<td>No vascular invasion</td>
<td></td>
</tr>
<tr>
<td>No regional nodal or distant metastases</td>
<td></td>
</tr>
</tbody>
</table>

- Transplantation is frequently the only surgical option due to liver dysfunction.
- Very good outcomes.
- Long wait times, unpredictable course.
Non-Surgical Management of HCC

Image guided

I. Transarterial
   - Chemo-embolization
   - Radio-embolization

II. Percutaneous puncture
   - Ethanol injection
   - Heat ablation
   - Cryo-ablation
   - Radiofrequency
   - Microwave

III. Extracorporial
   - HIFU (high intensity focused ultrasound)
Percutaneous Ethanol injection

- Absolute ethanol.
- Usually special needle.
- Usually multiple sessions (4-8 sessions).
Indications

• Small lesions < 5 cm in diameters and at risk for RFA i.e. adjacent to main biliary or to intestinal loops.

• In combination with other locoregional methods e.g. chemo-embolization or RFA to improve the results.
Ultrasound Guided Percutaneous Ethanol Injection

Pre-injection
Needle within tumor

Post-injection
Increased tumor echogenicity
has 1 main problem:
Non-uniform distribution of ethanol due to intra-tumoral septae

New needle
To solve the problem of non-uniform distribution of ethanol inside the tumor and to overcome the septations.
Injection of ethanol or acetic acid $\rightarrow$ cellular dehydration $\rightarrow$ tumor necrosis and fibrosis.

Replaced in popularity by RFA.
Radiofrequency ablation:

- Thermal necrosis to tumors by electromagnetic energy through needle electrodes.
- RFA versus resection for patients with single small lesions show comparable 1- and 3-year overall survival results, higher 1- and 3-year local recurrence rates.
- May be considered as a bridge to transplantation.
Patient Selection

I. Tumor Size:

- The ideal tumor is less than 3.5 cm but up to 5 cm included.
- Tumors between 3.5-7 cm in diameters are performed with special technique.
- Best outcomes are achieved in patients with Child A liver cirrhosis and tumors <2 cm in size.

II. Number of the tumors: the less the number the better the results.

III. Patients condition: Child C patients → contraindication. Bleeding profile should be acceptable.
IV. Vascular invasion and distant metastases: are contraindication

V. Location of the tumor:

- Tumors near the hilum are contraindicated for fear of main duct injury.

- Subcapsular tumors in close contact with intestinal loops are performed either intra-operative or after introduction of artificial ascites.

- Tumors close to large blood vessels are performed with temporary balloon occlusion of these vessels to prevent cooling effect of the blood flow or with local ethanol injection in the part adjacent to the vessel.
Radio-frequency has 1 main problem:

Only small tumor less than 5 cm

2 New Machines
To ↑ the ablation size > 5 cm

3- Combined therapy
5 – 7 cm lesion with saline infusion

6 cm tumor before RF ablation

After RF ablation with saline infusion
Lesions 5 – 7 cm

Three RF electrodes in the same time

Before RF ablation

After RF ablation
### Optimal Criteria

<table>
<thead>
<tr>
<th>Child-Pugh Class A/B</th>
<th>3 yr OS</th>
<th>78-87%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitary tumors &lt;5cm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Less side effects than PEI with better outcomes.
- Similar results to surgery in potentially resectable patients.
Tumor blood supply 95% from hepatic artery.

Chemo-embolization
Indications of Chemoembolization

- HCC unsuitable for neither surgery nor other minimally invasive therapy (RFA or PEI).

- In combination with other minimally invasive techniques (RFA and/or PEI) to obtain optimum results.

- Preoperative to reduce the tumor size to discover other non-visualized tumors which may be not seen by US, CT or MRI.

- Pre-liver transplantation for patients on waiting lists.
Contraindications

1-Poor liver functions:
   - Serum bilirubin > 3 mg/dL
   - SGOT > 100 IU/L
   - Serum Albumin < 3
   - LDH > 425 IU/L

2-Significant portal vein or hepatic vein invasion.

3-Ascites, recent variceal bleed, or significant thrombocytopenia.

4-Poor cardiac or renal function (creatinine >2.0).
Technique

Lipidol cytotoxic drug mixture

During injection

Very small pieces of gel foam
Mix the cytotoxic drug with Lipiodol and inject it in feeding artery. Embolise the feeding arteries → severe infarction and ischemia aggravating the effect of Lipiodol cytotoxic drug mixture.
Follow up

After 1 month

High lipidol concentration in CT

↓AFP
### Indications

- **Large unresectable HCC**

- **Prior to resection or RFA**

- **Palliative purposes**

- Intraarterial embolization with lipoidol and chemotherapy (doxorubicin or cisplatin).

- Standard palliative treatment for patients with unresectable HCC.
Additional Treatment Considerations

- Microwave Coagulation Therapy
- Interstitial Laser Hyperthermic Ablation
- Radiotherapy
- Adjuvant and Neoadjuvant Treatment
- Antiangiogenic agents
- Oncolytic viral agents
- Chemosensitizing agents.
Microwave ablation:

- It is a technique that destroys tumors by heating cells, resulting in localized areas of necrosis and tissue destruction. It appears promising and generally well tolerated, even in patients with limited hepatic reserve as it is effective in sparing uninvolved liver tissues (Lu et al., 2005).
Cryoablation:

- Intraoperative cryoprobe tumor insertion with alternating freeze/thaw cycles.
- Largely replaced by RFA.
- High complication rates.
Radiotherapy:

Recently, it had been shifted from palliative purposes to cure-oriented therapies, including three-dimensional conformal RT, stereotactic RT, proton therapy and Thera-Sphere radiation.

Indications

- Large unresectable HCC
- Symptomatic portal vein thrombosis
- Symptomatic jaundice
- Part of combined modality treatment
Gene therapy:

It is considered as a potential adjuvant to other therapies. Interventional therapies such as TACE and PEI provides new possibilities for the delivery of gene therapy vectors into hepatic tumours, subsequently, increasing the effectiveness and minimizing the potential side effects (Alcoceba et al., 2006).
Systemic therapies:

1- Chemotherapy :-

No single or combination chemotherapy regimen had been found to be particularly effective in HCC.

2-Hormonal treatment :-

Antiandrogen therapies and long acting octreotide were not effective in prolonging survival in patients with advanced HCC.
3-Interferon:-

Clinical trials in patients with HCC failed to demonstrate anti-tumor response to interferon.

4-Vitamin K:-

Treatment with high dose vitamin K does not affect survival in patients with advanced HCC.
Sorafinib

To solve the problems of new angiogenesis

(Sorafinib)

Block VEGF receptor

Inhibit new angiogenesis

Multi-Kinase inhibitor

↓ Cell proliferation

↑ apoptosis

• Systemic therapy is appropriate for patients with advanced unresectable HCC who are unsuitable for locoregional therapy.
Sorafenib Targets Both Tumor-Cell Proliferation and Angiogenesis

Tumor cell

- EGF/HGF
- Autocrine loop
- Apoptosis
- HIF-2
- SOX
- PI3K
- ROS

Endothelial cell or Pericyte

- PDGF-B
- VEGF
- Paracrine stimulation
- PDGFR-β
- VEGFR-2

Apoptosis

- Differentiation
- Proliferation
- Migration
- Tubule formation


Llovet ASCO 2007
EGYPTIAN GUIDELINES FOR HCC MANAGEMENT
1-Early stage disease:

*Includes patients with preserved liver function (Child-Pugh A,B) with solitary HCC or up to 3 nodules ≤3cm in size.

*These patients can be effectively treated by resection, liver transplantation or percutaneous ablation with possibility long term cure and 5 year survival figures ranging from 50%-75%.
2-Intermediate stage disease:

*Consists of  Child-Pugh class A/B patients with  large/multifocal HCC who do not have cancer related symptoms and do not have macrovascular invasion or extrahepatic spread.

*These are the optimal candidate for transarterial chemoembolization.
3-Advanced stage disease:

*Includes patients who present with cancer symptoms and/or with vascular invasion or extrahepatic spread.

*They have shorter life expectancy (50% survival at one year) and are candidates to enter therapeutic trials with the new agents.
4-End stage HCC:

Includes patients with extensive tumor involvement leading to severe deterioration of their physical capacity (performance status > 2 and/or major impairment of liver function (Child-Pugh class C).
### Egyptian performance status:

<table>
<thead>
<tr>
<th>Status</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal activity</td>
</tr>
<tr>
<td>1</td>
<td>Symptoms but ambulatory</td>
</tr>
<tr>
<td>2</td>
<td>In bed &lt; 50% of time</td>
</tr>
<tr>
<td>3</td>
<td>In bed &gt; 50% of time</td>
</tr>
<tr>
<td>4</td>
<td>Bed ridden 100%</td>
</tr>
</tbody>
</table>
The different modalities of TTT of HCC:

**Locoregional:**
* Percutaneous ethanol injection (PEI).
* Radiofrequency ablation (RFA).
* Transarterial chemoembolization.

**Surgical:**
* Resection
* Liver transplantation

**Palliative:**
* Sorafinib

**Systemic or elective chemotherapy:** Is not recommended and should not be considered as standard of care.
Surgical Treatment:

**Non cirrhotics:**
Resection in a single lesion.

**In cirrhotics:**
Liver transplantation for those fulfilling Milan criteria.

N.B. Preoperative therapy is considered if the waiting list exceeds 6 months.

Resection can be an alternative option for single lesion in those of stage A1 (normal bilirubin and no PH) with preserved liver function.

N.B. Pre or post-resection adjuvant therapy is not recommended.
Locoregional treatment:

If the size of the lesion

* $\leq 3\text{cm}$ ----- PEI = RFA

* $3-5\text{ cm}$ ----- RFA

Except difficult sites---PEI

---Surgical approach

* $5-7\text{ cm}$ (stage B) TACE followed by RFA/PEI

* $>7\text{ cm}$ (stage B) TACE (repeated) $\pm$ RFA/PEI
In cirrhotics:

*Stage A (Child A and B):

**Single tumour**
--- A1  LTx, resection- RFA/PEI
--- A2  LTx – RFA/PEI
--- A3  LTx- RFA/PEI

**Multiple (all ≤ 3cm)** --- A4  LTx- RFA/PEI

*Stage B (Child A and B):

--- If < 10cm TACE ± RFA/PEI
--- If > 10cm in Child A--- resection

**Large size** --- Sorafenib (if possible as supportive TTT)

*Stage C (Child A and B):

--- Vascular invasion --- Sorafenib.
--- Extrahepatic spread --- Conservative

*Stage D (Child C):

--- Within Milan criteria --- LTx.
--- Outside Milan criteria --- Conservative treatment
Post-treatment follow up:

*Laboratory investigations:

*Liver function tests (AST, ALT, Total and direct bilirubin, albumin, PT/INR).

*Kidney function tests (creatinine, urea, Na, K).

*AFP

*Radiology:

*Triphasic CT (Multislice if possible)

*Frequency of follow up:

1. One month after end of therapy
2. During 1st year F/U -- repeat every 3 month
3. During 2nd year F/U -- repeat CT every 6 month
   -- repeat LAB invest / 3 mo
4. After 2 ys -- repeat CT one/year
   -- repeat LAB investigations every 3 mo

AS LONG AS NO NEW LESIONS DEVELOPE.
Thank You